



REVIEW

Bilingual edition English/Spanish

Personalized antimicrobial therapy in critical and elderly patients

Terapia antimicrobiana personalizada en pacientes críticos y en edad avanzada

Santiago Grau^{1,6}, Marta de Antonio-Cuscó¹, Sara Ortonobes-Roig²,
Ibai Los-Arcos^{3,6}, María Jesús Jiménez⁴, Dolors Soy⁵

¹Pharmacy Department, Hospital del Mar, Barcelona. Spain. ²Pharmacy Department, Corporació Sanitària Parc Taulí, Sabadell (Barcelona). Spain.

³Department of Infectious Diseases, Hospital Vall d' Hebron, Barcelona. Spain. ⁴ Pharmacy Department, Hospital Universitario 12 de Octubre, Madrid. Spain.

⁵ Pharmacy Department, Hospital Clínic, Barcelona. Spain. ⁶Universitat Autònoma de Barcelona, Barcelona. Spain.

Author of correspondence

Santiago Grau
Hospital del Mar
Passeig Marítim, 25-19
08003 Barcelona. Spain.

Email:
sgrau@psmar.cat

Received 13 June 2021;
Accepted 13 August 2021.
DOI: 10.7399/fh.11760

How to cite this paper

Grau S, De Antonio-Cuscó M, Ortonobes-Roig S, Los-Arcos I, Jiménez MJ, Soy D. Personalized antimicrobial therapy in critical and elderly patients. *Farm Hosp.* 2021;45(Suppl 1):S64-76

Abstract

Objective: Personalized therapy in the treatment of infections is essential to ensure optimization of antimicrobial drug levels. This strategy, together with an understanding of the activity of these drugs, decreases the risk of bacterial resistance and improves the drugs' safety profile. Alternative routes of administration, such as inhalation, and the information provided by pharmacokinetic models, are essential given the limitation of antimicrobial activity allowed by the new antimicrobials.

Method: A non-systematic review of the literature is presented as a way of tackling and finding solutions to the problem. A search for high-quality articles on the research topic was conducted.

Results: A total of 370 articles were detected, which were subjected to a further selection to discard low quality papers by a team of five clinical pharmacists and an intensivist. Finally, 153 articles were included in the review.

Conclusions: The geriatric and the critical care patient population require the administration of antimicrobials with close monitoring. The routes of administration recommended for the first group are discouraged for the second. The inhaled route often results in high plasma concentrations in patients with respiratory infections. Pharmacokinetic models are a valuable tool in the treatment of geriatric patients, who are often excluded from clinical trials.

Resumen

Objetivo: La terapia personalizada en el tratamiento de las infecciones es esencial para garantizar la optimización de los niveles de fármaco alcanzados en el paciente tratado. Adicionalmente, esta estrategia, juntamente con el conocimiento de la actividad antimicrobiana de estos fármacos, disminuye la posibilidad de desarrollar resistencias bacterianas y mejora el perfil de seguridad de estos fármacos. Las terapias por vías alternativas, como la inhalada, y el soporte de la información facilitada por modelos farmacocinéticos son esenciales debido a la limitación de la actividad aportada por los nuevos antimicrobianos.

Método: Se presenta una revisión no sistemática de la literatura como medida de orientación de la problemática y soluciones a lo expuesto anteriormente. Se ha efectuado una búsqueda de artículos de alta calidad sobre el tópico planteado.

Resultados: Se detectaron 231 artículos que sufrieron una selección posterior, en base a la calidad de los trabajos valorada por un equipo de cinco farmacéuticos clínicos y un médico intensivista. Finalmente, se incluyeron 153 artículos que soportan la revisión que se ha desarrollado.

Conclusiones: La población geriátrica y la integrada por pacientes críticos presenta la necesidad de utilización de los antimicrobianos con una estrecha monitorización. Vías de administración recomendadas en la primera, están desaconsejadas en la segunda. La vía inhalada es una vía que suele relacionarse con elevadas concentraciones en pacientes con infecciones respiratorias. Los modelos farmacocinéticos son un soporte de gran valor para poblaciones como la geriátrica debido a que es mayoritariamente excluida de los ensayos clínicos.

KEYWORDS

Geriatrics; Critically ill patient; Antimicrobials;
Pharmacokinetics-pharmacodynamics; Inhaled route.

PALABRAS CLAVE

Geriatría; Paciente crítico; Antimicrobianos;
Farmacocinética-farmacodinamia; Vía inhalada.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Introduction

The need for personalized therapy in the field of infectious diseases stems from the fact that, historically, many clinical trials of antimicrobials have been carried out in wide-ranging populations with different characteristics, often overlooking those patients that require greater precision in the prescription of these drugs¹. The CORDIS programs are the main source of European Union funding for these purposes since 1990. These currently include the development of the program "Training towards personalized antibiotic treatment (TIPAT)", furnished with a total amount of almost €4M and having 2024 as its completion date¹. The aim of the program is to combat the threat from increased bacterial resistance, especially in the context of severe infections. The goal is to increase the efficacy of these therapies while minimizing the risk of resistance, and gaining knowledge about the interrelations between patients, pathogens and drugs within the action framework of TIPAT. It includes an interdisciplinary network with wide experience in the field and is designed to integrate the biological and pharmacological data associated with pathogen-patient interaction on the basis of personalized therapies. These programs attempt to integrate clinical pharmacology, immunology and microbiology with a view to producing innovative methodologies that allow for the personalization of antimicrobial therapy. The TIPAT is aimed at hospitals, the pharmaceutical industry and regulatory agencies, and is also designed to include scientific innovation that helps to control and reduce bacterial resistance by optimizing the use of antimicrobial agents.

Numerous factors, including patient status, microbiological etiology and infection site, are essential for the personalization of antimicrobial therapy². Furthermore, personalized therapy using the latest antimicrobial agents is

limited, making it necessary to resort to alternative administration routes when using these drugs.

The aim of the present review is to describe the most relevant information on personalized antimicrobial therapy in critical and older patients, as well as to gain knowledge regarding its application with the latest available antimicrobial agents.

Methods

The search of the literature included papers published on Medline from January 2000 to May 2021. This was a non-systematic review carried out by five hospital pharmacists and one intensive care specialist. The search identified 370 articles, of which 153 (41.4%) were selected after excluding studies that were not directly related to our review's objective.

Geriatric population

How to address the increasing average age of the population is, without a doubt, one of the challenges facing the Spanish health system. Estimates tell us that by 2050 one fourth of the world population will be made up of people of over 60 years of age³. The use of antibiotics in geriatric care is widespread⁴ and a balance between efficacy, safety and tolerability is not easy to guarantee⁵. If we focus on prescription of antimicrobials, it is thus necessary to be familiar with the pharmacokinetic and pharmacodynamic (pK/pD) alterations these agents undergo in association with old age, as well as their main pharmacological interactions and most common side effects⁶.

The principal barriers preventing proper therapeutic management of infections in the geriatric population are shown in Table 1.

Table 1. Challenges of antimicrobial therapy in geriatric patients

Challenge	Pathophysiology and impact	Antimicrobial examples
Diagnostic difficulties	Atypical presentation of infectious diseases Immunosenescence	– Inappropriate or unnecessary antimicrobial therapies
Pharmacokinetic and pharmacodynamic changes	Absorption: decreased gastric depletion, lower gastric motility, decreased gastric flow and pH alterations.	– Reduced bioavailability (azithromycin, itraconazole)
	Distribution: increased fatty tissue, decreased body water, sarcopenia, malnutrition, hypoalbuminemia	– Increased distribution volume of lipophilic antimicrobials (rifampicin, quinolones, macrolides, oxazolidinones) – Decreased distribution volume of hydrophilic antimicrobials (beta-lactams, aminoglycosides, glycopeptides) – Decreased plasma protein binding rate (ceftriaxone)
	Metabolism: decreased phase 1 metabolizing enzymes (cytochrome P450); no alterations of phase 2 metabolism	– Increased half-life of hepatically metabolized antimicrobials (macrolides, quinolones, antifungals, azoles, antiretrovirals)
	Elimination: decreased renal function	– Accumulation of renally eliminated antimicrobials (beta-lactams, glycopeptides, aminoglycosides, daptomycin, ciprofloxacin, levofloxacin, cotrimoxazole)
Practical aspects of drug administration	Parenteral administration (endovenous, intramuscular, subcutaneous)	– Alternative subcutaneous administration (ceftriaxone, cefepime, ertapenem)
	Enteral administration (oral, tubes)	– Incompatibilities with enteral nutrition (quinolones)
Prevention of adverse effects	Enhancement resulting from polypharmacy and comorbidities Increased risk of hospitalization	– Cardiotoxicity: macrolides, quinolones – Hematological toxicity: linezolid – Nephrotoxicity: vancomycin, colistin, aminoglycosides – Neurotoxicity: beta-lactams, quinolones, carbapenems – Gastrointestinal toxicity (<i>Clostridioides difficile</i> infection)
Pharmacological interactions	Polypharmacy: competition for cytochrome P450 Increased risk of adverse effects	– Myopathies: statins and macrolides – Digitalis intoxication: digoxin and macrolides – Hyperpotassemia: ACE inhibitors or ARBs and cotrimoxazole – Hypoglycemia: sulfonylureas and quinolones

ACE: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers.

Diagnostic difficulties

Different factors lead to alterations in the way infectious diseases present themselves in the elderly. These patients are normally afflicted with reduced integrity of physical barriers like the skin or the connective tissue. Immunosuppression is also frequent, and the general immune response to face new infections is of little effect⁷. As people age, immunosenescence increases the risk of morbimortality following infectious diseases⁹, due to alterations in cell function and systemic cytokine levels which negatively affect the immune system⁸. This all leads to nonspecific symptoms such as general disorientation, fatigue, falls or loss of weight, making it difficult to diagnose infections. This atypical presentation of disease has been recently associated with increased mortality⁹.

Changes in pK/pD

In the context of ageing, the pK/pD behavior of antibiotics is mostly affected by kidney function deterioration and patient frailty⁴. The main alterations take place in each of the pharmacokinetic (pK) stages of the drugs for the reasons described below.

Absorption: In the elderly, gastric depletion and motility are usually decreased, as is gastrointestinal blood flow, and the digestive pH suffers alterations¹⁰. This alters drug absorption, thus affecting antibiotic bioavailability. The incidence of achlorhydria in geriatric patients is high, reducing bioavailability levels of different antimicrobial agents¹¹. Lower drug availability is made worse by the frequent use of acidity suppressants or calcium salts¹². In addition, the decreased function of intestinal transporter glycoprotein-P can affect the bioavailability of some antibiotics¹⁰.

Distribution: Ageing increases the body's content in fat and reduces body water^{4,6}. Drugs that are soluble in fat, such as rifampicin, quinolones, macrolides, oxazolidinones, tetracyclines, amphotericin B and most imidazole antifungals, have their half-life extended due to an increased volume of distribution (Vd). In some chronic pathologies, like chronic heart failure or ascites due to cirrhosis of the liver, the amount of water in the body is increased, favoring the distribution of hydrophilic drugs like aminoglycosides, beta-lactam antibiotics and glycopeptides¹³. Loading doses of hydrophilic antibiotics are recommended in cases of severe infection in patients with increased body water¹³.

Variations in plasma protein levels in geriatric patients also affect drug distribution. Malnutrition and decreased albumin can also increase the free fraction of antibiotics¹³, which is especially important in drugs with high plasma protein binding (PPB) rates, such as ceftriaxone¹⁴. In contrast, the elderly usually exhibit higher concentrations of alpha-1-acid glycoprotein, which reduces the free fraction of basic antimicrobials like macrolides.

Metabolism: Older patients have a decreased blood flow and lower metabolic rates in the liver, which can increase the half-life of hepatically metabolized drugs¹⁵. Such is the case with macrolides, quinolones, antifungals and azoles, whose hepatic extraction fractions are high^{10,15}.

The metabolic activity of the liver depends on phase 1 and 2 metabolizing enzymes. As regards phase 1 enzymes, cytochrome P450 oxidases are decreased in older people, causing a slower metabolization rate of drugs that are CYP3A4 substrates¹⁶. However, phase 2 enzymes, such as transferases, are well preserved in the elderly, thus guaranteeing the biotransformation of drugs in the body, although it has been suggested that frailty may decrease phase 2 metabolism¹⁸.

Elimination: Clearance of antimicrobial agents is lower in geriatric patients because of the reduced excretory function of the lungs or the gastrointestinal system, although kidney function is the mainly affected one in this respect¹⁹. Comorbidities like high blood pressure, diabetes or cardiovascular disorders can aggravate kidney failure²⁰.

An impaired kidney function increases serum concentrations of drugs, creating a higher risk of toxicity from hydrophilic antibiotics, which are mostly excreted through the kidney⁴. When using antibiotics that have limited therapeutic margins or are dosed by body weight, it is very important to adjust the dosing with great precision, especially in the case of hydrophilic agents.

Different formulas are available to estimate renal clearance. The most widely used of these is the equation of Cockcroft and Gault, who in 1976 had already shown that a linear inverse correlation existed between kid-

ney function and age²¹. The Cockcroft-Gault equation is the recommended formula in geriatric populations, together with the CKD-EPI equation, which was validated in 2009²².

Practical aspects of drug administration

The skin of older patients is thinner and more susceptible to bruising. This, together with the highly prevalent use of anticoagulants in geriatric populations, can complicate the safe placement of endovenous catheters in these patients²³. Nonetheless, parenteral administration is widely used in extreme situations in which the patient's life is at risk⁶.

Intramuscular delivery is an alternative to endovenous administration, but it is not the method of choice in geriatric patients since it causes pain and is associated with a high risk of bruising. Because of this, subcutaneous administration is another parenteral approach that is widely used in geriatrics²⁴. This form of delivery has a lower risk of causing thrombosis and catheter related infections²⁵. The subcutaneous approach, which is not contraindicated in decoagulated patients²⁴ and is less painful than intramuscular administration, is of greater comfort and convenience to geriatric patients and may be used at home.

Following subcutaneous delivery, the drug must diffuse into the intravascular space, a step that reduces maximum concentration and delays maximum time as compared to endovenous delivery, although the area under the curve is usually similar. The subcutaneous route prolongs exposure to the drug, thereby optimizing the pK/pD parameters of time-dependent antibiotics like beta-lactam agents. Therefore, the most frequently used subcutaneous drugs are: ceftriaxone, cefepime, ceftazidime, ertapenem and –among glycopeptides– teicoplanin. Subcutaneous administration is not recommended for concentration-dependent antimicrobials like aminoglycosides or quinolones²⁴.

Disadvantages of subcutaneous delivery include the potential for causing edema or swelling, although these effects are infrequent (< 5%). Even so, it is not the approach of choice in emergency settings, since it does not allow for the administration of hyperosmolar solutions, and drug absorption depends on factors like perfusion and vascularization. Finally, it is not indicated in the presence of malnutrition or cachexia, which limits its use in geriatrics^{24,26,27}.

It should be added, in the case of oral administration, that dysphagia can impede drug delivery²⁸. This may be addressed by using pharmaceutical solutions or suspensions. Pharmacists can recommend the most appropriate form of preparation in the geriatric population, especially in patients who bear (nasogastric tubes).

Prevention of adverse effects

Age-related pK changes increase the risk of adverse effects associated with polypharmacy²⁹. In addition, some antibiotics may be directly associated with severe adverse effects in the geriatric population, especially when underlying conditions or interactions exist^{5,30}. A clear example of this is the presence of cardiovascular disease, which makes older people more vulnerable to the adverse effects of some antibiotics, like macrolides, that increase coronary-related mortality, while agents like quinolones prolong the QT interval and are associated with a higher risk of arrhythmia and a higher incidence of aortic aneurysms. The same family of drugs has been linked to increased levels of creatine kinase, having the potential for causing muscle toxicity in geriatric populations³¹.

These populations are especially susceptible to *Clostridioides difficile* infection³².

Pharmacological interactions

The efficacy of an antibiotic may be impaired because of concomitant administration of other drugs¹⁴. Proton pump inhibitors or histamine type 2 receptor antagonists reduce stomach acidity and interfere with the proper absorption of some antimicrobials like rilpivirine or posaconazole³³. Most pharmacological interactions, however, take place through cytochrome P450³⁴.

Frail geriatric patients are polymedicated and this increases their risk of adverse effects and pharmacological interactions³⁵ in situations requiring, for example, the concomitant prescription of macrolides and statins, which can cause rhabdomyolysis and acute kidney damage³⁶. A higher

risk of hospitalization for digitalis intoxication has also been reported in patients treated with digoxin and macrolides, and to a lesser extent with azithromycin³⁷. In the case of patients treated with ACE inhibitors or ARBs, potassium levels must be monitored when administering cotrimoxazole, since there is a greater risk of hyperpotasemia³⁸. Severe hypoglycemic episodes are also frequent in older patients when certain macrolides and quinolones are administered together with sulphonylureas³⁹. Finally, the prescription of antibiotics like ciprofloxacin or cotrimoxazole together with anticoagulant vitamin K antagonists can cause severe bleeding in elderly patients⁴⁰.

New antimicrobials in older patients

There are few studies on the use of the newly available antimicrobial agents (ceftazidime-avibactam, ceftolozane/tazobactam, meropenem/vaborbactam or isavuconazole) in geriatric patients. However, isolated cases of patients treated with these antimicrobials have been described. Coinfections with carbapenemase producing *Klebsiella pneumoniae* and the SARS-CoV-2 virus worsen the prognosis, especially in older patients, with high mortality rates in spite of the use of ceftazidime-avibactam⁴¹. In contrast, a single case of a geriatric patient suffering from meningitis who was successfully treated with this antibiotic has been reported⁴².

Given its antimicrobial spectrum and its safety and efficacy profile, ceftolozane/tazobactam has been proposed as an alternative in geriatric patients with skin and soft tissue infections or osteomyelitis⁴³. Although only 11% of patients in the pivotal ceftolozane/tazobactam studies were older than 75, a higher incidence of adverse effects was noted, and correct dose adjustment in accordance with the patient's kidney function is recommended^{44,45}.

In the case of the new antifungal agents, a phase 1 trial has been carried out to determine the pharmacokinetic profile of isavuconazole after a single oral dose in 48 healthy individuals, of which 24 were over 65 years of age. The study concluded that dose adjustment for age or sex is not required⁴⁶.

Critical patients in the adult population

Epidemiology of infections in intensive care units

Infections are one of the leading causes of morbimortality in intensive care units (ICUs), with mortality rates in excess of 50%⁴⁷. An estimated 51% of patients admitted to ICUs present active infection, while 71% receive antimicrobial treatment, at a cost accounting for up to 40% of total ICU expenditure⁴⁷.

ICU infections are usually the result or the consequence of the patient's critical illness⁴⁸. This population is particularly vulnerable to infection because of the disruption of the physical barriers of the body (invasive devices, surgery, trauma, etc.) and the alterations in both the innate and adaptive immune systems. As a result, these patients present with exacerbated inflammation, hyporesponsiveness and/or circulating neutrophils with decreased chemotaxis^{48,49}. Such imbalanced inflammatory and adaptive responses lead to tissue damage, sepsis, Acute Respiratory Distress Syndrome (ARDS) and/or multiorgan failure⁵⁰.

It should be noted that certain drugs commonly used in ICUs are associated with complications such as pneumonia infection followed by the reduction of cough and swallowing reflexes derived from neuromuscular blockade and sedoanalgesia⁵¹.

Of the pathogens isolated in critical care units, 67% are gram-negative microorganisms, while 37% and 16% are gram-positive microbes and fungi, respectively⁵².

Nosocomial infections are diagnosed in up to 32% of ICU patients and lead to a significant increase in mortality rates, especially in the presence of multi-resistant and extremely resistant microorganisms (MDRs/XDRs)⁵³ whose presence is mainly due to inappropriate use of antimicrobials, severity of illness, the insertion of central venous catheters and prolonged periods of hospitalisation⁵⁴.

The main barriers to adequate therapeutic management of infections in the adult ICU population are described in Table 2.

pK/pD alterations

Pharmacokinetic alterations

The efficacy of antimicrobial therapy is crucial for the survival of critically ill patients⁴⁷, the optimization of antimicrobial therapy should be a priority in the management of this population.

Absorption: Intravenous administration is the delivery route of choice in acute conditions, since the critically ill often suffer from enteric malabsorption⁵⁵. This results from mesenteric hypoperfusion caused by the redistribution of the blood flow towards the outside of the gastrointestinal tract in order to regulate cardiovascular homeostasis in the presence of shock⁵⁵. Such regional hypoperfusion may be enhanced by the action of vasoconstrictors⁵⁶. The use of subcutaneous and intramuscular antibiotics must therefore be avoided in these patients, in contrast to what applies in other populations.

In such settings, brief periods of enteral fasting may result in atrophy of the intestinal mucosa and loss of integrity of the tight junctions⁵⁷. Other factors affecting absorption may include gastrointestinal dysmotility enhanced by sedoanalgesia due to slowing of gastric emptying⁵⁸ alkalization of gastric pH due to prophylactic treatment of stress ulcers, preventing the passage of drugs of an acidic nature through the membranes; and/or loss of bioavailability of drugs when they are administered using a nasogastric tube⁵⁹.

Distribution: Volume of distribution (Vd) is increased during septic processes due to capillary permeability caused by epithelial damage resulting from stimulation of different endogenous mediators by bacterial endotoxins⁶⁰. All this has an effect on hydrophilic drugs because of their extracellular distribution, resulting in potentially suboptimal concentrations that may affect therapeutic efficacy⁶⁰ and pose a risk for the development of resistance⁶¹. Other factors that are common in critical patients, such as mechanical ventilation, extracorporeal circuits, ascites and pancreatitis, may also increase the Vd of drugs⁶².

The presence of hypoalbuminemia in 40-50% of critical patients⁶³ can have an influence on both Vd and clearance of antibiotics with high plasma protein binding (PPB) rates⁶⁴.

Increased clearance can also take place in the context of hyperbilirubinemia⁶⁵ or elevated alpha-1-glycoprotein values⁶⁵ because of displaced albumin.

Metabolism: Inflammation and immunosuppression associated with critical illness can alter the metabolizing enzymes of drugs, carriers and plasma proteins⁶⁶.

Elimination: Between 20% and 60% of critical patients can present with higher rates of renal clearance due to increased cardiac output and vasodilation resulting from Systemic Inflammatory Response Syndrome (SIRS)⁶⁷. Risk factors associated with the development of this condition include sepsis, surgery, trauma or burns⁶⁸. Renal hyperfiltration has a strong impact on the standard dosing regimens of drugs that are eliminated through the kidneys, leading to subtherapeutic concentrations and clinical failure⁶⁸.

At the other end of the spectrum, 78% of critical patients can suffer from acute kidney failure⁶⁹, making it necessary to reduce doses of drugs that are cleared through the kidneys in order to avoid toxic concentrations of antimicrobial agents.

An additional consideration is the impact of potential liver failure, which alters the rate of excretion of drugs that are subject to biliary elimination.

Extracorporeal techniques like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) may also have a significant impact on the elimination of certain antimicrobials, depending on the properties of the drugs themselves and on the techniques employed.

PK/PD optimization of the main families of ICU antimicrobials

Strategies for pK/pD optimization of the most common families of ICU antimicrobial agents are described below.

Aminoglycosides: Because of their hydrophilic nature, the Vd of these products is increased, leading to decreased maximum concentration (C_{max}) levels. Since their efficacy depends on concentration, one strategy is to optimize the length of dosing intervals to allow higher C_{max} values while reducing the risk of nephrotoxicity⁷⁰. Plasma monitoring of the drug's concentration and knowledge of its MIC value with reference to the pathogen are indispensable for adequate follow-up in these cases⁷⁰.

Table 2. Challenges of antimicrobial therapy in critical care patients

Challenge	Pathophysiology and impact	Observations and antimicrobial examples
Pharmacokinetic and pharmacodynamic changes	Absorption: malabsorption, decreased/increased gastric emptying, decreased/increased intestinal motility	<ul style="list-style-type: none"> - Decreased bioavailability: first pass effect (penicillin G, remdesivir), gastric pH alkalization resulting from prophylactic treatment of stress ulcers (ketoconazole, itraconazole), manipulation of the pharmaceutical presentation to administer by tube, interaction with enteral nutrition (quinolones), ion chelation (tetracyclines, ciprofloxacin) - Decreased bioavailability: decreased gastric emptying (doxycycline, isoniazid, minocycline, sulphonamides), interaction with enteral nutrition (itraconazole, nitrofurantoin) - Gastrointestinal dysmotility induced by sedoanalgesics - Increased gastrointestinal motility resulting from the use of prokinetic agents - Increased regional hypoperfusion caused by vasopressors - Atrophy of the intestinal mucosa resulting from prolonged fasting
	Distribution: increased capillary permeability, hypoalbuminemia, malnutrition, mechanical ventilation, extracorporeal circuits (renal replacement therapy, cardiopulmonary bypass, ECMO, drainage), ascites, pancreatitis, burn patients, hydric overload, hyperbilirubinemia Metabolism: inflammation and immunosuppression, alterations in drug metabolising enzymes, plasma carriers and proteins Elimination: hyperfiltration (sepsis, surgery, trauma, burn patients), kidney failure, CRRT, ECMO, alterations in hepatic excretion (bile duct obstruction, cholestasis, cirrhosis)	<ul style="list-style-type: none"> - Increased Vd of hydrophilic antimicrobials (beta-lactams, aminoglycosides, glycopeptides, linezolid, colistin) - The Vd of lipophilic antimicrobials (fluoroquinolones, macrolides, lincosamides, tigecycline) - Decreased PPB rates (ceftriaxone, daptomycin, ertapenem) - Drugs that are eliminated through the kidneys: beta-lactams, glycopeptides, aminoglycosides, daptomycin, ciprofloxacin, levofloxacin, cotrimoxazole, ganciclovir - Drugs that are eliminated through the liver: tigecycline, caspofungin - Drugs with high rates of extraction when using CRRT y ECMO (see Table 3)
Practical aspects of administration	Parenteral administration (endovenous, intramuscular, subcutaneous)	<ul style="list-style-type: none"> - Choice: intravenous route (bioavailability = 100%) - Avoid intramuscular and subcutaneous route, which are associated with erratic absorption in the presence of tissue hypoperfusion - Risk of extravasation
	Enteral administration (oral, tubes)	<ul style="list-style-type: none"> - Pharmaceutical formula not suited to grinding or and/or partitioning - Incompatibilities with enteral nutrition (quinolones) - Increased bioavailability with enteral nutrition (itraconazole, nitrofurantoin) - Chelation from ion interaction (tetracyclines, ciprofloxacin)
	Inhaled / nebulized administration	<ul style="list-style-type: none"> - Increased epithelial lining fluid (ELF) concentrations together with decreased systemic exposure (amikacin, colistin, tobramycin, vancomycin) - Risk of bronchospasm (pH and hyperosmolarity). The possibility of administering bronchodilators previously should be considered - Variable drug deposition: type of nebulizer; proper technique in mechanically ventilated patients; MV and nebulizer position in the circuit - Strategy for severe cases. Risk/benefit assessment - Increased CSF concentrations together with decreased systemic exposure (amikacin, liposomal amphotericin B and amphotericin B deoxycholate, caspofungin, colistin, daptomycin, gentamicin, teicoplanin, tigecycline, tobramycin, vancomycin)
	Intrathecal / epidural / intraventricular	<ul style="list-style-type: none"> - Dosing depends on drain aperture - Requirements: sterile and apyrogenous; free from solid particles (0.22 micron filter); isosmotic (292-297 mOsm/L); pH value approaching 7.32; preservative free; glucose serum contraindicated; volume, 2-5 mL
Prevention of adverse effects	Enhanced by polypharmacy and comorbidities Increased ICU and hospital stays	<ul style="list-style-type: none"> - Cardiotoxicity (QT interval prolongation): amphotericin B, atazanavir, azoles, chloroquine, macrolides, quinolones - Hemotoxicity: cotrimoxazole, ganciclovir, linezolid - Nephrotoxicity: aminoglycosides, acyclovir, colistin, vancomycin - Neurotoxicity: beta-lactams, carbapenems, quinolones - Gastrotoxicity (<i>Clostridioides difficile</i> infection)

Table 2 (cont.). Challenges of antimicrobial therapy in critical care patients

Challenge	Pathophysiology and impact	Observations and antimicrobial examples
Pharmacological interactions	Polypharmacy: competition for cytochrome P450 Increased risk of adverse effects	<ul style="list-style-type: none"> – Myopathies: statins and macrolides or daptomycin – Enhanced action of neuromuscular blockers: clindamycin, colistin, doxycycline, vancomycin – Digitalis intoxication: digoxin and macrolides – Increased risk of QT interval prolongation: amiodarone and voriconazole, haloperidol and azithromycin, methadone and levofloxacin – Hyperpotassemia: ACE inhibitors or ARBs and cotrimoxazole – Enhanced sedation: itraconazole and morphine, voriconazole y fentanyl – Decreased sedation: rifampicin and morphine, rifampicin and thiopental – Serotonin syndrome: linezolid and serotonin reuptake inhibitors – Drug-pathology interactions: myasthenia gravis and amikacin, cotrimoxazole and glucose-6-phosphate dehydrogenase deficiency
Development of multiresistances. PROA	Presence of risk factors that increase infections caused by multiresistant microorganisms Need for PROA programmes in ICUs	<ul style="list-style-type: none"> – Limited therapeutic armamentarium for multi-resistant bacteria – Antimicrobial pK/pD optimization depending on the drug's nature and pattern of antimicrobial activity

ACE: angiotensin-converting inhibitors; ARBs: angiotensin receptor blockers; CFS: cerebrospinal fluid; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; MV: mechanical ventilation; pD: pharmacodynamics; pK: pharmacokinetics; PPB: plasma protein binding; PROA: programmes for optimising the use of antibiotics; Vd: distribution volumen.

Beta-lactam agents: These highly hydrophilic drugs have an increased Vd which reduces their concentration levels considerably. It has been shown that prolonged administration and loading doses of these drugs makes it possible to achieve pK/pD goals, and thus achieve free concentrations four times higher than the MIC for 100% of the dosing interval ($100\% \text{ ft} \geq 4 \times \text{MIC}$)⁷¹. In cases of severe infection, in the absence of kidney failure, pneumonia or actual or suspected pathogens with lower sensitivity levels, the above should therefore be the strategy of choice⁷².

Fluoroquinolones: Due to their lipophilic nature, these drugs have a high distribution reaching optimal concentrations both at intracellular and extracellular levels and in neutrophils and lymphocytes⁷³. The pK of these antibiotics has a low impact on critical illness. However, based on previous experience in the presence of hyperfiltration and high MICs, doses of levofloxacin and ciprofloxacin might require being increased to 750 mg/24 h⁷⁴ and 400 mg/8 h⁷⁵ respectively. When dosing has to be adjusted it is preferable to lengthen the dosing intervals, since the activity of these agents is concentration dependent.

Glycopeptides (vancomycin): The drugs in this group are relatively hydrophilic antibiotics⁶⁴. Continuous infusion of vancomycin has shown to be superior to intermittent infusion: minimization of maximum plasma concentrations results in a 2.6 higher likelihood of reaching the pharmacokinetic goal, while reducing nephrotoxicity by 53%⁷⁶.

Lipopeptide (daptomycin): As a result of its high rate of PPB (%), clearance of the therapeutically active free fraction of this drug may be increased in conditions of hypoalbuminemia, hyperbilirubinemia and/or elevated alpha-1-glycoprotein⁶³. Therefore, achieving optimal efficacy parameters in critical populations usually requires doses reaching AUC/MIC values of up to 400 and 800 respectively for bacteriostatic or bactericidal action to have effect⁷⁷.

Oxazolidinones (linezolid): It has been observed⁷⁸ that 30 to 40% of patients treated with linezolid do not reach optimal pK/pD concentrations, which in the case of critical patients have been set at values of 80-120 for AUC/MIC⁷⁹ and a T > MIC of 100%⁸⁰. To achieve this, it could be necessary to prolong perfusion time and/or increase the dose in cases of obesity⁸¹ or hyperfiltration⁸² or in patients receiving CRRT⁸³, especially in individuals whose isolates exhibit high MIC values. Patients with kidney fail-

ure⁸⁴, or who are older⁸⁵, underweight or cirrhotic, can reach high plasma concentrations of the drug and develop linezolid induced thrombocytopenia as a result⁸⁶.

Table 3 shows ICU application of individualized new antimicrobial therapies.

Inhaled antimicrobial therapy as a strategy to improve respiratory drug concentrations

The use of nebulized antimicrobials maximizes drug concentration levels in the airways and the parenchyma of the lungs while minimizing systemic exposure and toxicity¹⁰⁷. The effectiveness of inhaled antimicrobials correlates with the amount of drug deposited in the lungs, which in turn depends on three main parameters: airway anatomy, patient ventilation and characteristics of drug delivery aerosols¹⁰⁸. The characteristics of the inhaled aerosol particles are the most easily adjustable factor and the one with greatest impact on the amount of drug that deposited in the airways and the parenchyma of the lungs. A nebulized drug that penetrates the alveolus peripheral regions of the lungs with an efficacy of 90% should be made up of particles whose mass median aerodynamic diameter (MMAD) is between 1 and 5 μm in size¹⁰⁹.

Nebulized antimicrobial treatment can be of use in different clinical scenarios, such as maintenance treatment to prevent respiratory exacerbations in patients with bronchiectasis (with or without cystic fibrosis) or patients with different respiratory infections like ventilator-associated pneumonia (VAP)¹⁰⁸. However, the effectiveness of nebulized antibiotics in the treatment of mechanical VAP continues to be controversial. The 2016 clinical guide of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) puts forward the weak recommendation (based on very poor quality evidence) that VAP caused by gram-negative bacilli, which are only sensitive to aminoglycosides or polymyxins, should be treated with both nebulized and systemic antibiotics¹¹⁰. Subsequently, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) suggested the avoidance of nebulized treatment in these cases because of the poor quality of the evidence¹¹¹. Finally, a meta-analysis including two new clinical trials in addition to the nine studies in the IDSA/

ATS 2016 clinical guidelines suggested a benefit from nebulized antibiotics in the complementary treatment of VAP¹². This benefit is mainly observed in infections caused by multi-resistant gram-negative bacilli with few therapeutic options.

The most important data on nebulized antimicrobial agents are described below.

Antibiotics

Aminoglycosides

Tobramycin is the most widely used aminoglycoside in nebulized form. One meta-analysis showed that nebulized tobramycin afforded the greatest benefit in long-term treatment for *Pseudomonas aeruginosa* infection in cystic

Table 3. Individualization of new intensive care units antimicrobial therapies

Antimicrobial	Antimicrobial properties	Optimal pK/pD index	Dose optimization strategy	Dosing adjustments	Dosing in extracorporeal techniques
Ceftazidime/ avibactam Standard dose: 2 g/0.5 g every 8 hours via 2 hour perfusion ⁸⁷	CAZ: Hydrophilic (log P = -1.6) ¹³⁴ MP = 456.5 Da ¹³⁴ PPB < 10% ¹³⁴ Vd = 0.21-0.28 L/kg ¹³⁴ Renal excretion: 85% unmodified ⁸⁸ Biliary excretion < 1% ⁸⁸	CAZ: %100 ft > 4 x MIC ⁸⁹	Administration of loading dose followed by prolonged or continuous perfusion ⁹⁰ : Based on ceftazidime data: 15 mg/kg + 6 g on continuous infusion (CrCl < 60 mL/min) ⁹¹	Renal impairment: depending on perfusion: Prolonged over 2 h: - CrCl 31-50: 1 g/0.25 g every 8 hours ⁸⁷ - CrCl 16-30 mL/min: 0.7 g/0.1875 g every 12 hours ⁸⁷ - CrCl 6-15 mL/min: 0.7 g/0.1875 g every 24 hours ⁸⁷ Continuous (based on ceftazidime data): The loading dose should not be adjusted - CrCl 31-50 mL/min: 4 g/1 g on continuous perfusion pump in 24 hours ⁹¹ - CrCl 11-29 mL/min: 2 g/0.5 g on continuous perfusion pump in 24 hours ⁹² Hepatic impairment: not required ⁸⁷	IHD (dialyses 80% ⁸⁸): 1 g/0.25 every 24 hours (after dialysis ⁸⁸) CVVHF: 1 g/0.25 g every 8 hours ⁹³ CVVHD: 2 g/0.5 g every 8 hours ¹⁹⁴ Clearance depends significantly on the dialysate rate. AVI clearance is rapid, especially at high dialysate rates ⁹⁵ CVVHDF: 2 g/0.5 g every 8 hours at dialysate rates of 1.5 L/g ⁸⁸ ECMO: data not available for CAZ-AVI. For CAZ the literature suggests little impact ⁹⁶ , although prolonged therapies could be associated with increased plasma concentration levels of the drug
	AVI: Hydrophilic (log P = -3,6) ¹³⁴ MP = 265.25 Da ¹³⁴ PPB = 5.7-8.2% ¹³⁴ Vd = 0.3 L/kg ¹³⁴ Renal excretion: 95% unmodified ⁸⁸	AVI: %ft > CT			
Ceftolozane/ tazobactam Standard dose: 1 g/0.5 g-2 g/1 g every 8 hours via 1 hour perfusion ⁹⁷	CEF: Hydrophilic (log P ceftolozane = -6,2) ¹³⁴ MP = 666.7 Da ¹³⁴ PPB = 30% ¹³⁴ Vd = 0.2 L/kg ¹³⁴ Renal excretion: 95% unmodified ⁸⁸	CEF: %100 ft > 4 x MIC ⁸⁹	Administration of loading dose followed by prolonged or continuous perfusion ⁹⁸	Renal impairment: - CrCl > 50 mL/min: IAI and UTI: 1 g/0.5 g every 8 hours ⁹⁷ VAP and HAP: 2 g/1 g every 8 hours ⁹⁷ - CrCl 30-50 mL/min: IAI and UTI: 0.5 g/0.25 g every 8 hours ¹²⁹ VAP and HAP: 1 g/0.5 every 12-8 hours, 0.5 g/0.25 g every 8 hours ⁹⁷ - CrCl 15-29 mL/min: IAI and UTI: 250 mg/125 mg every 8 hours ⁹⁷ VAP and HAP: 500 mg/25 mg every 8 hours ⁹⁷ - CrCl < 15 mL/min: 1 g/0.5 g every 24 hours IAI and UTI: 500 mg/250 mg loading dose followed by 100 mg/50 mg every 8 hours ⁹¹ VAP and HAP: 1.5/0.75 g loading dose followed by 300 mg/150 mg every 8 hours ⁹¹ Hepatic impairment: not required ⁹⁷	IHD (dialyses 60% ⁸⁸): IAI and UTI: 500 mg/250 mg loading dose followed by 100 mg/50 mg every 8 hours (after dialysis) ⁹⁷ VAP and HAP: 1.5/0.75 g loading dose followed by 300 mg/150 mg every 8 hours (after dialysis) ⁹⁷ Alternative: 1 g/0.5 g loading dose 3 days per week after dialysis ⁸⁸ CVVHF and CVVHD: 1 g/0.5 g every 8 hours ^{88,99} CVVHDF: 2 g/1 g every 8 hours ⁸⁸ ECMO: increased Vd ⁹¹ ; minimum CS ⁹¹ . Decrease of 37% in tazobactam clearance ⁸⁸ . No adjustment is required ⁸⁸
	TAZ: Hydrophilic (log P tazobactam = -1.4) ¹³⁴ MP = 300.29 Da ¹³⁴ PPB = 16-21% ¹³⁴ Vd = 0.3 L/kg ¹³⁴ Renal excretion: 70% unmodified ⁸⁸	TAZ: % ft > CT			

Table 3 (cont.). Individualization of new intensive care units antimicrobial therapies

Antimicrobial	Antimicrobial properties	Optimal pK/pD index	Dose optimization strategy	Dosing adjustments	Dosing in extracorporeal techniques
Meropenem/vaborbactam Standard dose: 2 g/2 g every 8 hours via 3 hour perfusion ¹⁰⁰	MER: Hydrophilic (log P = -0.6) ¹³⁴ MP = 383.5 Da ¹³⁴ PPB = 2% ¹³⁴ Vd = 0.25 L/kg ¹³⁴ Renal excretion: 70% unmodified ⁸⁸ Biliary excretion: minimal ⁸⁸	%100 ft > 4 x MIC ⁸⁹	Administration in prolonged, 3 hour perfusion ¹⁰⁰ Based on meropenem data: 2 g/2 g every 8 hours on continuous infusion ⁹¹	Renal impairment: - CrCl 39-20 mL/min: 2 g/2 g every 8 hours ¹⁰¹ - CrCl 19-10 mL/min: 1 g/1 g every 12 hours ¹⁰¹ - CrCl < 10 mL/min: 0.5 g/0.5 g every 12 hours ¹⁰¹ Hepatic impairment: not required ¹⁰¹ Continuous (based on meropenem data): The loading dose should not be adjusted - CrCl 30-49 mL/min: 1 g/1 g every 8 hours on continuous infusion ⁹¹ - CrCl 10-29 mL/min: 1 g/1 g every 12 hours on continuous infusion ⁹¹	IHD (dialyses < 50% ⁸⁸): 0.5 g/0.5 g every 12 hours after dialysis ⁸⁸ CVVHF: 0.5 g/0.5 g every 8 hours for a flow rate of 1-2 L/h or 1 g/1 g every 8 hours for a flow rate of 3-4 L/h ⁸⁸ CVVHD: no data available for MER-VAB CVVHDF: no data available for MER-VAB. For MER: 1 g-2 g/8 h ⁸⁸ ECMO: no data available for MER-VAB; however, the literature suggests very little impact from MER (increased Vd, minimal CS) ⁹¹
	VAB: Hydrophilic (log P = 1.02) ¹³⁴ MP = 297.14 Da ¹³⁴ PPB = 33% ¹³⁴ Vd = 0,3 L/kg ¹³⁴ Renal excretion: 80-90% unmodified ⁸⁸	% ft > CT			
Isavuconazole Standard iv/oral dose: 200 mg every 8 hours for 48 hours + 200 mg every 24 hours (12 hours or 24 hours after the loading dose) ¹⁰²	Highly lipophilic (log P = 4.14) ¹³⁴ MP = 437.5 Da ¹³⁴ PPB > 99% ¹³⁴ Vd = 5 L/kg ¹³⁴ Renal excretion 40% inactive metabolites and < 1% like isavuconazole ⁸⁸	f AUC/MIC = 25-50 ¹⁰³	Loading dose: 200 mg every 8 h x 6 doses (48 hrs) ⁸⁸ Maintenance dose: 200 mg daily (beginning 12-24 hrs after last loading dose) ⁸⁸	Renal impairment: no adjustment required, even in terminal kidney failure cases ¹⁰² Hepatic impairment: in Child-Pugh class C cases it might be necessary to reduce the dose by 50%. This should be avoided if possible ¹⁰⁴	The characteristics of isavuconazole might cause it to exhibit plasma concentration alterations in the presence of extracorporeal techniques. Monitoring of the drug's concentration levels is recommended It does not dialyse, and therefore does not require adjustments during dialysis ¹⁰² . In one case of a patient on sustained low efficiency dialysis a reduction of 42% in ISA concentrations was reported ¹⁰⁵ ECMO: one case was reported of high sequestration and deposition of isavuconazole on the circuit. Doubling of the standard dose could be required ¹⁰⁶

AVI: avibactam; CAZ: ceftazidime; CEF: ceftolozane; CrCl: creatinine clearance; CRRT: continuous renal replacement therapy; CS: circuit sequestration; CVHD: continuous venovenous hemodialysis; CVHDF: continuous venovenous hemodiafiltration; CVHF: continuous venovenous hemofiltration; fAUC/MIC: area under the unbound drug concentration-time curve; fCMI > MIC: percentage of a 24-h time period that the unbound drug concentration exceeds the MIC; HAP: pulmonary hypertension arterial; IHD: intermittent hemodialysis; ISA: isavuconazole; MER: meropenem; MP: molecular weight; PPB: plasma protein binding; PPB: plasmatic protein binding; TAZ: Tazobactam; VAB: vaborbactam; VAP: ventilator associated pneumonia; Vd: distribution volume.

fibrosis patients¹¹³. The high doses required and the need for prolonged use, however, create some concern regarding its potential renal toxicity, which has been described in some specific cases^{114,115}.

Another drug of this group that is used in nebulized form is amikacin. The risk of systemic absorption with the standard formulation is similar to that of endovenous amikacin and can cause potential side effects¹⁰⁸. Nebulized liposomal amikacin, a newly developed formulation, increases local concentration of the drug while reducing its systemic absorption. Its use in patients with cystic fibrosis was well tolerated, but did not show to be superior to conventional nebulized tobramycin¹¹⁶. In one clinical trial, nebulized liposomal amikacin produced a higher negativization

rate of germ cultures when it was added to standard treatment of pulmonary infections with *Mycobacterium avium* complex that were resistant to conventional treatment¹¹⁷. It has thus become a promising new drug in the treatment regimen of respiratory infections caused by nontuberculous mycobacteria.

Colistin

Nebulized colistin is formulated as colistimethate sodium, which subsequently becomes colistin sulfate *in vivo*¹⁰⁸. It is, so far, the most frequently used nebulized antibiotic in the treatment of respiratory infections caused by multi-resistant gram-negative bacilli. A variety of doses is used in

VAP patients, ranging from 1 million IUs every 12 hours to 5 million IUs every 8 hours¹⁰⁸, making it difficult to compare the data. Although one meta-analysis showed a lower mortality rate when nebulized colistin was added to endovenous colistin to treat VAP¹¹⁸, the usefulness of nebulized antimicrobials in the context of VAP, as pointed out before, continues to be controversial, as are the adequate dosing levels of colistin in its nebulized form. Given that systemic absorption of nebulized colistimethate sodium is practically null, no nephrotoxicity associated to nebulized treatment has been described¹¹⁵.

Aztreonam

Aztreonam lysine is a nebulized drug formulation that has been approved for the treatment of *P. aeruginosa* infection in patients diagnosed with cystic fibrosis¹⁰⁷. However, it has not been shown to have a similar benefit in clinical trials including patients with non-cystic fibrosis bronchiectasis¹¹⁹.

Fluoroquinolones

Among the antibiotics in this group, nebulized ciprofloxacin has been given the most frequent use. Specifically, a liposomal ciprofloxacin formulation was used in phase 3 clinical trials in patients with non-cystic fibrosis bronchiectasis. The results of the two clinical trials that were conducted turned out to be contradictory: one of them showed a benefit, over time, in preventing respiratory exacerbations, while the other did not confirm this finding¹²⁰. Further studies are, therefore, needed to determine the potential benefits of this nebulized drug in daily clinical practice.

Antifungals

Nebulized amphotericin B

Nebulized amphotericin B, especially in its liposomal formulation, has been widely used for antifungal prophylaxis in lung transplant patients¹²¹. Although no clinical trials are available for this population, the data published in different studies are favorable in terms of drug's long-term effectiveness, tolerability and influence on respiratory function tests^{122,123}. On the basis of accumulated experience in prophylaxis, it has also been used for antifungal therapy, but studies are limited to case descriptions¹²⁴.

Azoles

Experience with nebulized azoles is more limited, but some studies have shown that the physico-chemical characteristics of both posaconazole and voriconazole are well suited to nebulisation¹²⁵. Cases of lung transplant patients with invasive fungal infections, treated adequately with these nebulized azoles have already been reported^{125,126}.

Echinocandins

The physico-chemical characteristics of micafungin and anidulafungin have been described as appropriate for nebulisation¹²⁷. Two cases were recently reported of lung transplant patients with tracheobronchitis from *Scopulariopsis* spp. who were treated successfully with nebulized micafungin¹²⁸. These drugs could, therefore, be potentially used on an individualized basis in these infections, which are difficult to treat and exhibit resistance to most antifungal agents.

Personalization of antimicrobial therapy using pK/pD models

An essential strategy in personalizing antimicrobial therapy consists in developing pK/pD models. Optimization of antimicrobial treatment requires knowledge of the pK/pD behavior of drugs following the administration of a given dose. The inherent variability of life (intraindividual, interindividual, in LADME processes and in terms of efficacy and/or toxicity regarding results) makes such optimization difficult. Measuring this variability, as well as identifying and quantifying the different factors that contribute to it, will help in the task of optimizing dosing regimens with adequate precision^{129,130}.

Antibiotic therapy and population models. Studies of pK/pD in different populations make it possible to: (i) quantify pK parameter alterations of

a drug in a given group of patients and determine intra- and interindividual variability; (ii) individualize/optimize dosing regimens on the basis of administered doses and blood concentration levels of the drug and population pK parameters; (iii) make recommendations on how to estimate optimal initial doses using clinical variables that are easily available at no further cost^{130,131}.

The goal is to reach biophase concentration levels of the antibiotic that can eradicate the microorganism without causing toxic effects. The use, in clinical practice, of mathematical-statistical models based on pK/pD concepts makes it easier to predict therapeutic results and to design optimal dosing regimens¹³¹.

The information provided by the pK/pD population models is the basis for individualization after dosing. Knowledge of the drug's individual pK parameters (and individual concentration-time profiles) is required in order to relate them to the pharmacodynamic value associated to effect and toxicity. In the case of antimicrobials, the most widely accepted pD variable is the drug's MIC for the microorganism that is causing the infection.

The creation in antibiotic therapy of population pK/pD models for a given patient population provides information about the individuals included in the study and makes it possible to extrapolate to new patients within the same population in real time, using optimized initial and maintenance doses on the basis of the previously described pK/pD values.

The inclusion of covariables in the model allows for refinement and optimization of dosing regimens in special situations, such as: kidney failure, extreme old age, biochemical alterations, etc.^{132,133}. The model also incorporates pK/pD process variability at different levels^{134,135}.

These models are clearly an ideal tool for application and use in patient populations that are not included in clinical trials and for whom information on antimicrobial dosing and side effects may be contradictory, limited or even unknown. The models, however, can never serve as replacements for clinical trials in patients.

Table 4 shows the main advantages and drawbacks of pK/pD models^{134,135}.

Population modelling. The application of pK in clinical practice requires the definition of specific mathematical-statistical models describing the evolution of drug concentrations over time. Such models are defined by mathematical equations that include the pK parameters associated with the drug's characteristic behavior and make it possible to predict what the concentration-time values will be following the administration of known doses of a given drug¹³⁶.

The most common methods currently employed for estimating pK parameters can be divided into two main groups: (i) individual pK estimation methods and (ii) population pK estimation methods. The former ones assess the pK of a drug in an individual without considering the variability of pK parameters of other individuals. The latter aim at identifying and quantifying drug concentration variability among individuals belonging to a given population after receiving standard doses of a drug¹³⁶.

Individualization of antibiotic dosing regimens is a good example of personalized therapy. Therapeutic monitoring of drug's blood concentration levels following a known dose of the antimicrobial agent is the tool employed to this end. PK monitoring, which is highly advisable in clinical practice, requires certain indispensable data for interpretation purposes (Table 5). After obtaining blood samples of an antimicrobial agent following the administration of a known dose of the drug, individual pK parameters (profile of concentration-time values) can be estimated, and

Table 4. Advantages and inconvenients of pK/pD models

Advantages	Inconvenients
Rapid access to data and results as compared to clinical trials	Need for prior premises and assumptions that must be as rigorous, precise and accurate as possible
Cost savings	The model's robustness must be fully guaranteed The mathematical-statistical techniques used for model validation can be complex and slow to run

Table 5. pK monitoring in clinical practice¹³⁷

Required data
– One or more serum concentrations of the antibiotic (pK)
– Population pK parameters (estimated in advance)
– Software application (Bayesian method)
– Therapeutic target: pK/pD index

pD: pharmacodynamic; pK: pharmacokinetic .

the ideal pK/pD relationship for the antimicrobial type or family can be defined. This information is the basis for dosing regimen optimization. The calculation is performed using nonlinear regression mathematical-statistical analysis and the Bayesian method, since it is possible to estimate individual pK parameters on the basis of information regarding the drug's pK behavior within a given population (*a priori* data). Integration of population pK data and local or regional MIC values for a given microorganism or antibiotic makes it possible to evaluate, by means of Monte Carlo simulations, the model's predictive capacity in terms of optimizing the pK/pD values of different dosing regimens of the antibiotic. These approaches help to make recommendations regarding initial antimicrobial dosing regimens, with a view to optimizing therapy from the very beginning of the treatment period on the basis of the covariables that have an influence on its variability.

PK models with the new antimicrobial agents. In the case of the new antibiotics, there is one study in patients with cystic fibrosis (CF) and infectious exacerbations caused by *P. aeruginosa*¹³⁸. In this populational pK/pD model, the study's authors showed that the plasma clearance of cefto-

lozane/tazobactam was comparable to that of adult patients without CF. In contrast, a decreased central Vd was observed in patients with CF. On the basis of these data, the probability of reaching the therapeutic goal ($f_{T > MIC} : 60\%$) was assessed using Monte Carlo simulations, suggesting that a dose of 1.5 g/8 h, infused for 60 minutes, would reach the therapeutic target in 39%, 60% and 100% of cases for MIC values of 8, 4 and 2 mg/L, respectively. It was also shown that for a dose of 3 g/8 h, these same percentages optimized the therapeutic goal for MIC values of 16, 8 and 4 mg/L, respectively. These data will contribute to the optimization of dosing regimens in future CF patients.

Isavuconazole is a new antifungal for the treatment of invasive aspergillosis and mucormycosis. A pK population model was used to assess dose adjustment needs in patients with hepatic impairment¹³⁹. The drug's clearance was found to decrease as a function of the degree of hepatic involvement, while the Vd was influenced by the patient's body mass index. These data made it possible to simulate the pK profiles of patients with varying degrees of hepatic impairment and to show that, in such patients, the average concentrations of isavuconazole in static balance exceed by less than twice the minimum concentration observed in healthy individuals, and that no side effects occur. In these conditions it was determined that isavuconazole did not require dose adjustment in patients with moderate liver failure.

Funding

No funding.

Conflict of interest

No conflicts of interests.

Bibliography

- Training towards Personalized Antibiotic Treatment. TIPAT Project. H2020. CODIS. European Commission [Internet] [accessed 06/06/2021]. Available at: <https://cordis.europa.eu/project/id/861323/es>
- Moser C, Lerche CJ, Thomsen K, Hartvig T, Schierbeck J, Jensen PØ, et al. Antibiotic therapy as personalized medicine - general considerations and complicating factors. *APMIS*. 2019;127(5):361-71. DOI: 10.1111/apm.12951. PMID: 30983040
- Harper S. Economic and social implications of aging societies. *Science*. 2014;346(6209):587-91.
- Pea F. Pharmacokinetics and drug metabolism of antibiotics in the elderly. *Expert Opin Drug Metab Toxicol*. 2018;14(10):1087-100. DOI: 10.1080/17425255.2018.1528226
- Pea F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. *Curr Opin Pharmacol*. 2015;24:18-22. DOI: 10.1016/j.coph.2015.06.006
- Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. *Clin Interv Aging*. 2018;13:657-67. DOI: 10.2147/CIA.S133640
- Scott MM, Liang SY. Infections in Older Adults. *Emerg Med Clin North Am*. 2021;39(2):379-94. DOI: 10.1016/j.emc.2021.01.004
- Rodrigues LP, Teixeira VR, Alencar-Silva T, Simonassi-Paiva B, Pereira RW, Pogue R, et al. Hallmarks of aging and immunosenescence: Connecting the dots. *Cytokine Growth Factor Rev*. 2021;59:9-21. DOI: 10.1016/j.cytogr.2021.01.006
- Hyernard C, Breining A, Duc S, Kobeh D, Dubos M, Prevel R, et al. Atypical Presentation of Bacteremia in Older Patients Is a Risk Factor for Death. *Am J Med*. 2019;132(11):44-1352.e1. DOI: 10.1016/j.amjmed.2019.04.049
- Maher D, Ailabouni N, Mangoni AA, Wiese MD, Reeve E. Alterations in drug disposition in older adults: a focus on geriatric syndromes. *Expert Opin Drug Metab Toxicol*. 2021;17(1):41-52. DOI: 10.1080/17425255.2021.1839413
- Levison ME, Levison JH. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. *Infect Dis Clin North Am*. 2009;23(4):791-815. DOI: 10.1016/j.idc.2009.06.008
- Utilización de medicamentos antiulcerosos en España durante el periodo 2000-2012. Informe de utilización de medicamentos U/AUL/V1/15012014. Ministerio de Sanidad, Servicios Sociales e Igualdad [Internet] [accessed 06/06/2021]. Available at: <https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antiulcerosos.pdf>
- Jump RLP, Canaday DH. Aging Has Unique Effects on the Risks, Presentation, Diagnosis, Treatment, and Prognosis of Infectious Diseases. *Infect Dis Clin North Am*. 2017;31(4):xiii-xv. DOI: 10.1016/j.idc.2017.08.001
- Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. *Clin Infect Dis*. 2005;40(7):997-1004.
- Tan JL, Eastment JG, Poudel A, Hubbard RE. Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. *Drugs and Aging*. 2015;32(12):999-1008.
- Cotreau MM, Von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. *Clin Pharmacokinet*. 2005;44(1):33-60.
- Kinirons MT, O'Mahony MS. Drug metabolism and ageing. *Br J Clin Pharmacol*. 2004;57(5):540-4.
- Wynne H. Drug metabolism and ageing. *J Br Menopause Soc*. 2005;11(2):51-6.
- Noreddin A, El-Khatib W, Haynes V, El-Khatib W. Optimal Dosing Design for Antibiotic Therapy in the Elderly: A Pharmacokinetic and Pharmacodynamic Perspective. *Recent Pat Antiinfect Drug Discov*. 2008;3(1):45-52.
- Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. *Expert Opin Drug Metab Toxicol*. 2015;11(4):491-508.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31-41.
- Levey AS, Stevens LA, Fricp C, Schmid CH, Zhang YL, Iii AFC, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-12.
- Moist LM, Lok CE, Vachharajani TJ, Xi W, Aljaishi A, Polkinghorne KR, et al. Optimal hemodialysis vascular access in the elderly patient. *Semin Dial*. 2012;25(6):640-8. DOI: 10.1111/sdi.12037
- Hernández-Ruiz V, Forestier E, Gavazzi G, Ferry T, Grégoire N, Breilh D, et al. Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When. *J Am Med Dir Assoc*. 2021;22(1):50-5.e6. DOI: 10.1016/j.jamda.2020.04.035
- Azevedo EF, Barbosa LA, De Bortoli Cassiani SH. Subcutaneous administration of antibiotics: An integrative literature review. *ACTA Paul Enferm*. 2012;25(6):817-22.
- Caccialanza R, Constans T, Cotogni P, Zaloga GP, Pontes-Arruda A. Subcutaneous Infusion of Fluids for Hydration or Nutrition: A Review. *J Parenter Enter Nutr*. 2018;42(2):296-307.
- Duems-Noriega O, Ariño-Blasco S. Subcutaneous fluid and drug delivery: Safe, efficient and inexpensive. *Rev Clin Gerontol*. 2015;25(2):117-46.

28. Sura L, Madhavan A, Carnaby G, Crary MA. Dysphagia in the elderly: Management and nutritional considerations. *Clin Interv Aging*. 2012;7:287-98.
29. Hilmer SN, Gnjjidic D. The effects of polypharmacy in older adults. *Clin Pharmacol Ther*. 2009;85(1):86-8.
30. Levison ME. Use of Selected Antibiotics in the Elderly Topical Collection on Infectious Diseases in the Elderly. *Curr Geriatr Reports*. 2015;4(1):105-15.
31. Falcone M, Paul M, Tiseo G, Yahav D, Prendki V, Friberg LE, et al. Considerations for the optimal management of antibiotic therapy in elderly patients. *J Glob Antimicrob Resist*. 2020;22:325-33. DOI: 10.1016/j.jgar.2020.02.022
32. Khosravi AMS. Disruption of the gut microbiome as a risk factor for microbial infections. *Curr Opin Microbiol*. 2013;16(2):221-7.
33. Zhou Q, Li W, Zeng S, Yu LS. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. *Ther Clin Risk Manag*. 2013;9(1):259-71.
34. Preissner S. Drug Interactions Involving the Cytochrome P450 Enzymes: Analysis of Common Combinations of Antibiotics and Pain Relieving Drugs. *J Drug Metab Toxicol*. 2012;03(05).
35. Cullinan S, O'Mahony D, O'Sullivan D, Byrne S. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. *Age Ageing*. 2016;45(1):115-20.
36. Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi SMM. Statin Toxicity From Macrolide Antibiotic Coprescription. *Ann Intern Med*. 2013;158(12):869-76.
37. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: A population-based study. *Clin Pharmacol Ther* [Internet]. 2009;86(4):383-6. DOI: 10.1038/clpt.2009.127
38. Antoniou T, Gomes T, Juurlink DN, Loufy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: A population-based study. *Arch Intern Med*. 2010;170(12):1045-9.
39. Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonyleureas. *JAMA Intern Med*. 2014;174(10):1605-12.
40. Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. *Am J Med*. 2012;125(2):183-9. DOI: 10.1016/j.amjmed.2011.08.014
41. Dumitru I, Dumitrascu M, Vlad N, Cernat R, Ilie-Serban C, Hangan A, et al. Carbapenem-Resistant *Klebsiella pneumoniae* Associated with COVID-19. *Antibiotics*. 2021;10(5):561. DOI: 10.3390/antibiotics10050561
42. Holyk A, Belden V, Lee JJ, Musick WW, Keul R, Britz GW, et al. Ceftazidime/avibactam use for carbapenem-resistant *Klebsiella pneumoniae* meningitis: A case report. *J Antimicrob Chemother*. 2018;73(1):254-6.
43. Diehl B, Sánchez I, Arcenillas P, Cuchi E, Gómez I, González de Molina FJ, et al. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant *Pseudomonas aeruginosa*: clinical and microbiological outcomes. *Int J Antimicrob Agents*. 2018;51(3):498-502. DOI: 10.1016/j.ijantimicag.2017.11.003
44. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-UTI). *Lancet*. 2015;385(9981):1949-56. DOI: 10.1016/S0140-6736(14)62220-0
45. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-clAI). *Clin Infect Dis*. 2015;60(10):1462-71.
46. Desai AV, Han D, Kowalski DL, Lademacher C, Pearlman H, Yamazaki T. No dose adjustment for isavuconazole based on age or sex. *Antimicrob Agents Chemother*. 2019;63(6):1-8.
47. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. *JAMA*. 2009 [accessed 23/01/2019];302(21):2323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19952319>
48. Martin SJ, Yost RJ. Infectious diseases in the critically ill patients. *J Pharm Pract*. 2011;24(1):35-43.
49. Marshall JC, Charbonney E, Gonzalez PD. The Immune System in Critical Illness. *Clin Chest Med*. 2008;29(4):605-16. DOI: 10.1016/j.ccm.2008.08.001
50. Bermejo-Martín JF, Martín-Loeches I, Bosinger S. Inflammation and infection in critical care medicine. *Mediators Inflamm*. 2014;2014:456256.
51. Brusselsaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. *Ann Intensive Care*. 2011;1(1):47.
52. Vincent JL, Sakr Y, Singer M, Martín-Loeches I, MacHado FR, Marshall JC, et al. Prevalence and Outcomes of Infection among Patients in Intensive Care Units in 2017. *JAMA*. 2020;323(15):1478-87.
53. Despotovic A, Milosevic B, Milosevic I, Mitrovic N, Cirkovic A, Jovanovic S, et al. Hospital-acquired infections in the adult intensive care unit—Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. *Am J Infect Control*. 2020;48(10):1211-5. DOI: 10.1016/j.ajic.2020.01.009
54. López-Pueyo MJ, Barcenilla-Gaite F, Amaya-Villar R, Garnacho-Montero J. Multi-resistencia antibiotica en unidades de criticos. *Med Intensiva*. 2011;35(1):41-53.
55. Huynh D, Nguyen NQ. Intestinal absorption and enteral nutrition support during critical illness. In: *Diet and Nutrition in Critical Care* [Internet]. New York: Springer; 2015 [accessed 13/05/2021], p. 1297-311. Available at: https://link.springer.com/referenceworkentry/10.1007/978-1-4614-7836-2_95
56. Krejci V, Hillebrand LB, Sigurdsson GH. Effects of epinephrine, norepinephrine, and phenylephrine on microcirculatory blood flow in the gastrointestinal tract in sepsis. *Crit Care Med*. 2006;34(5):1456-63.
57. Vermette D, Hu P, Canarie MF, Funaro M, Glover J, Pierce RW. Tight junction structure, function, and assessment in the critically ill: a systematic review. *Intensive Care Med Exp*. 2018;6(1):1-18. DOI: 10.1186/s40635-018-0203-4
58. Nguyen NQ, Chapman MJ, Fraser RJ, Bryant IK, Burgstad C, Ching K, et al. The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. *Intensive Care Med*. 2008;34(3):454-60. DOI: 10.1007/s00134-007-0942-2
59. Zhu LL, Zhou Q. Therapeutic concerns when oral medications are administered nasogastrically. *J Clin Pharm Ther*. 2013;38(4):272-6.
60. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med*. 2009;37(3):840-51. DOI: 10.1097/CCM.0b013e3181961bff
61. Bengtsson-Palme J, Larsson DGJ. Concentrations of antibiotics predicted to select for resistant bacteria: Proposed limits for environmental regulation. *Environ Int*. 2016;86:140-9. DOI: 10.1016/j.envint.2015.10.015
62. Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. *J Intensive Care Soc*. 2015;16(2):147-53. DOI: 10.1177/1751143714564816
63. Uldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. *Clin Pharmacokinet*. 2011;50(2):99-110.
64. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med*. 2009;37(3):840-51.
65. Brodersen R. Competitive Binding of Bilirubin and Drugs to Human Serum Albumin Studied by Enzymatic Oxidation. *J Clin Invest*. 1974;54(6):1353-64. DOI: 10.1172/JCI107882
66. Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL. Inflammation and pharmacokinetics: potential implications for HIV-infection. *Expert Opin Drug Metab Toxicol*. 2017;13(6):641-50. DOI: 10.1080/17425255.2017.131323
67. Beunders R, Schütz MJ, van Groenendaal R, Leijte GP, Kox M, van Eijk LT, et al. Endotoxemia-Induced Release of Pro-inflammatory Mediators Are Associated With Increased Glomerular Filtration Rate in Humans in vivo. *Front Med (Lausanne)*. 2020;7:559671. DOI: 10.3389/fmed.2020.559671
68. Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing. *Antibiotics*. 2020;9(7):1-12.
69. Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. *Crit Care Res Pract*. 2013;2013:479730. DOI: 10.1155/2013/479730
70. Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. *Semin Respir Crit Care Med*. 2007;28(6):596-603.
71. Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). *Crit Care*. 2019;23(1):104. DOI: 10.1186/s13054-019-2378-9
72. Taccone FS, Laupland KB, Montravers P. Continuous infusion of β -lactam antibiotics for all critically ill patients? *Intensive Care Med*. 2016;42(10):1604-6.
73. Smith RP, Baltch AL, Franke MA, Michelsen PB, Bopp LH. Levofloxacin penetrates human monocytes and enhances intracellular killing of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *J Antimicrob Chemother*. 2000;45(4):483-8.
74. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. *Antimicrob Agents Chemother*. 1998;42(5):1098-104. DOI: 10.1128/AAC.42.5.1098

75. Roberts JA, Alobaid AS, Wallis SC, Perner A, Lipman J, Sjövall F. Defining optimal dosing of ciprofloxacin in patients with septic shock. *J Antimicrob Chemother.* 2019;74(6):1662-9.
76. Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis. *Crit Care Med.* 2020;48(6):912-8. DOI: 10.1097/CCM.0000000000004326
77. Grégoire N, Marchand S, Ferrandière M, Lasocki S, Seguin P, Vourc'h M, et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. *J Antimicrob Chemother.* 2019;74(1):117-25. DOI: 10.1093/jac/dky374
78. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: A retrospective monocentric analysis. *Antimicrob Agents Chemother.* 2010;54(11):4605-10.
79. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme. *Clin Pharmacokinet.* 2003;42(15):1411-23.
80. Saravolatz LD, Pea F, Viale P. The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients? *Clin Infect Dis.* 2006;42(12):1764-71. DOI: 10.1086/504383
81. Corcione S, Pagani N, Baietto L, Fanelli V, Urbino R, Ranieri VM, et al. Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. *J Antimicrob Chemother.* 2015;70(8):2417-8. DOI: 10.1093/jac/dkv126. Erratas en: *J Antimicrob Chemother.* 2015;70(10):2925
82. Morata L, Cuesta M, Rojas JF, Rodríguez S, Brunet M, Casals G, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. *Antimicrob Agents Chemother.* 2013;57(4):1913-7.
83. Ide T, Takesue Y, Ikawa K, Morikawa N, Ueda T, Takahashi Y, et al. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy. *Int J Antimicrob Agents.* 2018;51(5):745-51. DOI: 10.1016/j.ijantimicag.2018.01.021
84. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. *J Antimicrob Chemother.* 2013;68(9):2128-33.
85. Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. *Br J Clin Pharmacol.* 2017;83(8):1758-72.
86. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. *Infection.* 2014;42(6):1007-12.
87. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica. Zavicefta 2 g/0,5 g polvo para concentrado para solución para perfusión. Internet [accessed 03/06/2021]. Available at: https://cima.aemps.es/cima/dochtml/ft/1161109001/FT_1161109001.html
88. Mensa J, Soriano A, López-Suñé E, Llinares P, Barberán J, Zboromyrska Y. Guía de Terapéutica Antimicrobiana 2021. Ficha Técnica Stribild con texto revisado en mayo 2013 31ª Ed. Antares. 2021.
89. Delattre IK, Taccone FS, Jacobs F, Hites M, Dugernier T, Spapen H, et al. Optimizing β -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? *Expert Rev Anti Infect Ther.* 2017;15(7):677-88.
90. Goncette V, Layios N, Descy J, Fripiat F. Continuous Infusion, Therapeutic Drug Monitoring and Outpatient Parenteral Antimicrobial Therapy with Ceftazidime-Avibactam: a Retrospective Cohort Study. *J Glob Antimicrob Resist.* 2021;0:17.
91. Sanford Guide. App Version 5.0.4. Antimicrobial Therapy, Inc. 2020.
92. Nicolau DP, McNabb JC, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. *Int J Antimicrob Agents.* 2001;17(6):497-504. DOI: 10.1016/S0924-8579(01)00329-6
93. Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. *Antimicrob Agents Chemother.* 2017;61(7).
94. Soukup P, Faust AC, Edgipanti V, Putnam WC, McKinnell JA. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. *Pharmacotherapy.* 2019;39(12):1216-22.
95. Bunnell KL, Wenzler E, Danziger LH, Rodvold KA. Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model. *Open Forum Infect Dis.* 2017;4(suppl_1):S294-S295.
96. Kühn D, Metz C, Seiler F, Wehrfritz H, Roth S, Alqudrah M, et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. *Crit Care.* 2020;24(1):1-11. DOI: 10.1186/s13054-020-03397-1
97. Agencia Española de Medicamentos y Productos Sanitarios. Ficha Técnica Zerbaxa. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1151032001/FT_1151032001.htm
98. Pilmis B, Petitjean G, Lesprit P, Lafaurie M, El Helali N, Le Monnier A, et al. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. *Eur J Clin Microbiol Infect Dis.* 2019;38(8):1457-61.
99. Sime FB, Lässig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, et al. A population pharmacokinetic model-guided evaluation of ceftolozane-tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. *Antimicrob Agents Chemother.* 2020;64(1):1-11.
100. Vaborem [Ficha técnica]. Available at: https://cima.aemps.es/cima/dochtml/ft/1181334001/FT_1181334001.html
101. Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT, eds. Guía Sanford de terapéutica antimicrobiana. México: Editorial Médica AWWESA; 2019.
102. Agencia Española de Medicamentos y Productos Sanitarios. Ficha Técnica Cresemba. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1181334001/FT_1181334001.html
103. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole pharmacodynamic target determination for Candida species in an in Vivo murine disseminated candidiasis model. *Antimicrob Agents Chemother.* 2013;57(11):5642-8.
104. Huang H, Xie H, Chaphekar N, Xu R, Venkataraman R, Wu X. A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. *Antimicrob Agents Chemother.* 2021;65(5):e02032-20.
105. Lahmer T, Baires GB, Heilmair M, Schmid RM, Sörgel F, Kinzig M, et al. Influence of sustained low-efficiency dialysis treatment on isavuconazole plasma levels in critically ill patients. *Antimicrob Agents Chemother.* 2019;63(11):1-4.
106. Zhao Y, Seelhammer TG, Barreto EF, Wilson JW. Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation. *Pharmacotherapy.* 2020;40(1):89-95.
107. Debnath SK, Srivastava R, Debnath M, Omri A. Status of inhalable antimicrobial agents for lung infection: progress and prospects. *Expert Rev Respir Med.* 2021;15(10):1251-70. DOI: 10.1080/17476348.2021.1919514
108. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. *Clin Microbiol Rev.* 2016;29(3):581-632.
109. Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy.* 2010;30(6):562-84. DOI: 10.1592/phco.30.6.562
110. Kalil AC, Metesky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63(5):e61-111.
111. Rello J, Solé-Leonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect.* 2017;23(9):629-39.
112. Sweeney DA, Kalil AC. Why don't we have more inhaled antibiotics to treat ventilator-associated pneumonia? *Clin Microbiol Infect.* 2019;25(10):1195-9. DOI: 10.1016/j.cmi.2019.04.018
113. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. *Cochrane Database Syst Rev.* 2018;3(3):CD001021. DOI: 10.1002/14651858.CD001021.pub3
114. Langley A, Cottingham L. Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation. *Am J Health Syst Pharm.* 2011;68(15):1385-6. DOI: 10.2146/ajhp100683
115. Trone DJ, Hall EA. Therapeutic drug monitoring of inhaled tobramycin in a post-hematopoietic cell transplant patient with bronchiolitis obliterans and end-stage renal disease. *J Pediatr Pharmacol Ther.* 2020;25(5):451-4.
116. Bilton D, Pressler T, Fajac I, Clancy JP, Sands D, Minic P, et al. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. *J Cyst Fibros.* 2020;19(2):284-91.
117. Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease cau-

- sed by *Mycobacterium avium* complex (CONVERT) a prospective, open-label, randomized study. *Am J Respir Crit Care Med.* 2018;198(12):1559-69.
118. Liu D, Zhang J, Liu HX, Zhu YG, Qu JM. Intravenous combined with aerosolized polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: A systematic review and meta-analysis. *Int J Antimicrob Agents.* 2015;46(6):603-9. DOI: 10.1016/j.ijantimicag.2015.09.011
 119. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, De Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. *Lancet Respir Med.* 2014;2(9):738-49.
 120. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with *Pseudomonas aeruginosa* (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. *Lancet Respir Med.* 2019;7(3):213-26.
 121. De Mol W, Bos S, Beeckmans H, Lagrou K, Spriet I, Verleden GM, et al. Antifungal Prophylaxis After Lung Transplantation: Where are We Now? *Transplantation.* 2021 Feb 22. DOI: 10.1097/TP.0000000000003717
 122. Monforte V, Ussetti P, Gavalda J, Bravo C, Laporta R, Len O, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for *Aspergillus* infection prevention in lung transplantation. *J Hear Lung Transplant.* 2010;29(5):523-30.
 123. Peghin M, Monforte V, Martín-Gómez MT, Ruiz-Camps I, Berastegui C, Saez B, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of *Aspergillus* spp. infection in lung transplantation. *Transpl Int.* 2016;29(1):51-62. DOI: 10.1111/tri.12679
 124. Godet C, Cateau E, Ramaert B, Grosset M, Le Moal G, Béraud G, et al. Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by *Hormoglyphiella aspergillata*: Case Report and Literature Review. *Mycopathologia.* 2017;182(7-8):709-13.
 125. Thanukrishnan H, Corcoran TE, Isabella CJ, Moore CA, Nero JA, Morrell MR, et al. Aerosolization of Second-generation Triazoles: In Vitro Evaluation and Application in Therapy of Invasive Airway Aspergillosis. *Transplantation.* 2019;103(12):2608-13.
 126. Solé A, García-Robles AA, Jordá C, Cases Viedma E, Mancheño N, Poveda-Andrés JL, et al. Salvage therapy with topical posaconazole in lung transplant recipients with invasive *Scedosporium* infection. *Am J Transplant.* 2018;18(2):504-9.
 127. Gómez-Ganda L, Terradas-Campanario S, Company-Herrero D. Physicochemical characterization of micafungin and anidulafungin for its nebulized administration. *Farm Hosp.* 2019;73(5):163-5.
 128. Los-Arcos I, Berastegui C, Martín-Gómez MT, Grau S, Company-Herrero D, Deu M, et al. Nebulized micafungin treatment for *Scopulariopsis* / *Microascus* tracheobronchitis in lung transplant recipients. *Antimicrob Agents Chemother.* 2021;65(6):e02174-20. DOI: 10.1128/AAC.02174-20
 129. Whiting B, Kelman AW, Grevel J. Population Pharmacokinetics Theory and Clinical Application. *Clin Pharmacokinet.* 1986;11(5):387-401.
 130. Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetic decision making. *Clin Pharm.* 1984;3(5):525-30.
 131. García MJ, Santos MD, Fernández De Gatta MM, Otero MJ, Domínguez-Gil A. Farmacocinética de poblaciones: una aproximación a la optimización del tratamiento con antimicrobianos. *Enferm Infecc Microbiol Clin.* 2001;19(5):219-28.
 132. Soy D, Torres A. Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. *Curr Opin Crit Care.* 2006;12(5):477-82.
 133. Horcajada JP. Aplicabilidad de los parámetros PK/PD de los antimicrobianos en el tratamiento de infecciones complejas y resistencias extremas. *Rev Esp Quimioter.* 2015;28:16-8.
 134. Doménech Berrozpe J, Martínez Lanao J, Peraire Guitart C, eds. Tratado general de Biofarmacia y Farmacocinética. Volumen II: Vías de administración de fármacos: aspectos biofarmacéuticos. Farmacocinética no lial y clínica. Madrid: Síntesis; 2013.
 135. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. *Annu Rev Pharmacol Toxicol.* 1992;32:185-209.
 136. Sheiner LB. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods. *Drug Metab Rev.* 1984;15(1-2):153-71.
 137. Abdul-Aziz MH, Alffenaar JWC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. *Intensive Care Med* [Internet]. 2020;46(6):1127-53. DOI: 10.1007/s00134-020-06050-1
 138. Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL. Population pharmacokinetics and safety of ceftazidime-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation. *Antimicrob Agents Chemother.* 2016;60(11):6578-84.
 139. Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment. *Antimicrob Agents Chemother.* 2016;60(5):3025-31. DOI: 10.1128/AAC.02942-15